{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:48Z","timestamp":1793747088340,"version":"4.6.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK117058"],"award-info":[{"award-number":["K23DK117058"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R03DK129631"],"award-info":[{"award-number":["R03DK129631"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001063","name":"Crohn's and Colitis Foundation of America","doi-asserted-by":"publisher","award":["Litwin Pioneers in IBD"],"award-info":[{"award-number":["Litwin Pioneers in IBD"]}],"id":[{"id":"10.13039\/100001063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40259-022-00522-0","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T07:03:45Z","timestamp":1648019025000},"page":"197-203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases"],"prefix":"10.1007","volume":"36","author":[{"given":"Mehak","family":"Bassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-7269","authenticated-orcid":false,"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"522_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"Global Burden of Diseases Collaborators","year":"2017","unstructured":"Global Burden of Diseases Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13\u201327.","journal-title":"N Engl J Med"},{"key":"522_CR2","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","volume":"381","author":"ZJ Ward","year":"2019","unstructured":"Ward ZJ, Bleich SN, Cradock AL, et al. Projected US state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381:2440\u201350.","journal-title":"N Engl J Med"},{"key":"522_CR3","doi-asserted-by":"publisher","first-page":"w822","DOI":"10.1377\/hlthaff.28.5.w822","volume":"28","author":"EA Finkelstein","year":"2009","unstructured":"Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28:w822\u201331.","journal-title":"Health Aff (Millwood)"},{"key":"522_CR4","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378.","journal-title":"Lancet"},{"key":"522_CR5","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cgh.2020.01.028","volume":"18","author":"AN Ananthakrishnan","year":"2020","unstructured":"Ananthakrishnan AN, Kaplan GG, Ng SC. Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century. Clin Gastroenterol Hepatol. 2020;18:1252\u201360.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"522_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","volume":"13","author":"M Versini","year":"2014","unstructured":"Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13:981\u20131000.","journal-title":"Autoimmun Rev"},{"key":"522_CR7","unstructured":"Chan SSM, Chen Y, Casey K, et al. Obesity is associated with increased risk of Crohn's disease, but not ulcerative colitis: a pooled analysis of five prospective cohort studies. Clin Gastroenterol Hepatol. 2021."},{"key":"522_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","volume":"14","author":"S Singh","year":"2017","unstructured":"Singh S, Dulai PS, Zarrinpar A, et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14:110\u201321.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"522_CR9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cgh.2019.11.009","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh S, Picardo S, Seow CH. Management of inflammatory bowel diseases in special populations: obese, old, or obstetric. Clin Gastroenterol Hepatol. 2020;18:1367\u201380.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"522_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.14309\/ajg.0000000000000197","volume":"114","author":"A Jain","year":"2019","unstructured":"Jain A, Nguyen NH, Proudfoot JA, et al. Impact of obesity on disease activity and patient-reported outcomes measurement information system (PROMIS) in inflammatory bowel diseases. Am J Gastroenterol. 2019;114:630\u20139.","journal-title":"Am J Gastroenterol"},{"key":"522_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cgh.2018.07.004","volume":"17","author":"NH Nguyen","year":"2019","unstructured":"Nguyen NH, Ohno-Machado L, Sandborn WJ, et al. Obesity is independently associated with higher annual burden and costs of hospitalization in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:709\u201318.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"522_CR12","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS ONE. 2018;13:e0195123.","journal-title":"PLoS ONE"},{"key":"522_CR13","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMra1907607","volume":"385","author":"DC Baumgart","year":"2021","unstructured":"Baumgart DC, Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N Engl J Med. 2021;385:1302\u201315.","journal-title":"N Engl J Med"},{"key":"522_CR14","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1093\/ibd\/izy189","volume":"24","author":"A Hemperly","year":"2018","unstructured":"Hemperly A, Sandborn WJ, Vande CN. Clinical pharmacology in adult and pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:2527\u201342.","journal-title":"Inflamm Bowel Dis"},{"key":"522_CR15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","volume":"56","author":"M Rosario","year":"2017","unstructured":"Rosario M, Dirks NL, Milch C, et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet. 2017;56:1287\u2013301.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 3","key":"522_CR16","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1002\/jcph.374","volume":"55","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice. J Clin Pharmacol. 2015;55(Suppl 3):S39-50.","journal-title":"J Clin Pharmacol"},{"key":"522_CR17","doi-asserted-by":"publisher","first-page":"802078","DOI":"10.1155\/2010\/802078","volume":"2010","author":"CR Balistreri","year":"2010","unstructured":"Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010;2010:802078.","journal-title":"Mediators Inflamm"},{"key":"522_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/MOG.0000000000000116","volume":"30","author":"L Kredel","year":"2014","unstructured":"Kredel L, Batra A, Siegmund B. Role of fat and adipokines in intestinal inflammation. Curr Opin Gastroenterol. 2014;30:559\u201365.","journal-title":"Curr Opin Gastroenterol"},{"key":"522_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04946.x","volume":"35","author":"E Bultman","year":"2012","unstructured":"Bultman E, de Haar C, van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn\u2019s disease patients. Aliment Pharmacol Ther. 2012;35:335\u201341.","journal-title":"Aliment Pharmacol Ther"},{"key":"522_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/MEG.0b013e32835d1f15","volume":"25","author":"M Bhalme","year":"2013","unstructured":"Bhalme M, Sharma A, Keld R, et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn\u2019s disease? Eur J Gastroenterol Hepatol. 2013;25:543\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"522_CR21","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1097\/MIB.0000000000000560","volume":"21","author":"JL Seminerio","year":"2015","unstructured":"Seminerio JL, Koutroubakis IE, Ramos-Rivers C, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:2857\u201363.","journal-title":"Inflamm Bowel Dis"},{"key":"522_CR22","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/apt.14665","volume":"47","author":"S Kurnool","year":"2018","unstructured":"Kurnool S, Nguyen NH, Proudfoot J, et al. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018;47:1472\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"522_CR23","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1097\/MIB.0b013e31829cf401","volume":"19","author":"JW Harper","year":"2013","unstructured":"Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2118\u201324.","journal-title":"Inflamm Bowel Dis"},{"key":"522_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41395-018-0104-x","volume":"113","author":"S Singh","year":"2018","unstructured":"Singh S, Proudfoot J, Xu R, et al. Obesity and response to infliximab in patients with inflammatory bowel diseases: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol. 2018;113:883\u20139.","journal-title":"Am J Gastroenterol"},{"key":"522_CR25","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/ibd\/izaa214","volume":"27","author":"ECL Wong","year":"2021","unstructured":"Wong ECL, Marshall JK, Reinisch W, et al. Body Mass index does not impact clinical efficacy of Ustekinumab in Crohn\u2019s disease: a post hoc analysis of the IM-UNITI trial. Inflamm Bowel Dis. 2021;27:848\u201354.","journal-title":"Inflamm Bowel Dis"},{"key":"522_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/art.30136","volume":"63","author":"R Klaasen","year":"2011","unstructured":"Klaasen R, Wijbrandts CA, Gerlag DM, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011;63:359\u201364.","journal-title":"Arthritis Rheum"},{"key":"522_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/rheumatology\/ket433","volume":"53","author":"E Gremese","year":"2014","unstructured":"Gremese E, Bernardi S, Bonazza S, et al. Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatol (UK). 2014;53:875\u201381.","journal-title":"Rheumatol (UK)"},{"key":"522_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","volume":"74","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74:813\u20137.","journal-title":"Ann Rheum Dis"},{"key":"522_CR29","doi-asserted-by":"crossref","unstructured":"Gu P, Chhabra A, Chittajallu P, et al. Visceral adipose tissue volumetrics inform odds of treatment response and risk of subsequent surgery in ibd patients starting antitumor necrosis factor therapy. Inflamm Bowel Dis. 2021.","DOI":"10.1093\/ibd\/izab167"},{"key":"522_CR30","doi-asserted-by":"publisher","first-page":"e00233","DOI":"10.14309\/ctg.0000000000000233","volume":"11","author":"Z Lim","year":"2020","unstructured":"Lim Z, Welman CJ, Raymond W, et al. The effect of adiposity on anti-tumor necrosis factor-alpha levels and loss of response in crohn\u2019s disease patients. Clin Transl Gastroenterol. 2020;11:e00233.","journal-title":"Clin Transl Gastroenterol"},{"key":"522_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1473-3099(06)70523-0","volume":"6","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis. 2006;6:438\u201346.","journal-title":"Lancet Infect Dis"},{"key":"522_CR32","doi-asserted-by":"publisher","first-page":"e00380","DOI":"10.14309\/ctg.0000000000000380","volume":"12","author":"S Singh","year":"2021","unstructured":"Singh S, Heien HC, Sangaralingham L, et al. Obesity is not associated with an increased risk of serious infections in biologic-treated patients with inflammatory bowel diseases. Clin Transl Gastroenterol. 2021;12:e00380.","journal-title":"Clin Transl Gastroenterol"},{"key":"522_CR33","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ijo.2015.64","volume":"39","author":"S Upala","year":"2015","unstructured":"Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int J Obes (Lond). 2015;39:1197\u2013202.","journal-title":"Int J Obes (Lond)"},{"key":"522_CR34","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","volume":"73","author":"MND Di Minno","year":"2014","unstructured":"Di Minno MND, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers. Ann Rheum Dis. 2014;73:1157\u201362.","journal-title":"Ann Rheum Dis"},{"key":"522_CR35","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1007\/s11695-020-04729-4","volume":"30","author":"R Garg","year":"2020","unstructured":"Garg R, Mohan BP, Ponnada S, et al. Safety and efficacy of bariatric surgery in inflammatory bowel disease patients: a systematic review and meta-analysis. Obes Surg. 2020;30:3872\u201383.","journal-title":"Obes Surg"},{"key":"522_CR36","doi-asserted-by":"crossref","unstructured":"Reenaers C, de Roover A, Kohnen L, et al. Bariatric surgery in patients with inflammatory bowel disease: a case-control study from the GETAID. Inflamm Bowel Dis. 2021.","DOI":"10.1093\/ibd\/izab249"},{"key":"522_CR37","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/ecco-jcc\/jjab037","volume":"15","author":"KH Allin","year":"2021","unstructured":"Allin KH, Jacobsen RK, Ungaro RC, et al. Bariatric surgery and risk of new-onset inflammatory bowel disease: a nationwide cohort study. J Crohns Colitis. 2021;15:1474\u201380.","journal-title":"J Crohns Colitis"},{"key":"522_CR38","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jama.2014.10397","volume":"312","author":"BC Johnston","year":"2014","unstructured":"Johnston BC, Kanters S, Bandayrel K, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA. 2014;312:923\u201333.","journal-title":"JAMA"},{"key":"522_CR39","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1001\/jama.2016.7602","volume":"315","author":"R Khera","year":"2016","unstructured":"Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424\u201334.","journal-title":"JAMA"},{"key":"522_CR40","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2018.7777","volume":"320","author":"ES LeBlanc","year":"2018","unstructured":"LeBlanc ES, Patnode CD, Webber EM, et al. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;320:1172\u201391.","journal-title":"JAMA"},{"key":"522_CR41","first-page":"CD010410","volume":"4","author":"CE Parker","year":"2018","unstructured":"Parker CE, Nguyen TM, Segal D, et al. Low dose naltrexone for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2018;4:CD010410.","journal-title":"Cochrane Database Syst Rev"},{"key":"522_CR42","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.intimp.2005.12.007","volume":"6","author":"D Brustolim","year":"2006","unstructured":"Brustolim D, Ribeiro-dos-Santos R, Kast RE, et al. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol. 2006;6:903\u20137.","journal-title":"Int Immunopharmacol"},{"key":"522_CR43","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.gastro.2003.02.004","volume":"125","author":"S Kane","year":"2003","unstructured":"Kane S, Altschuler EL, Kast RE. Crohn\u2019s disease remission on bupropion. Gastroenterology. 2003;125:1290.","journal-title":"Gastroenterology"},{"key":"522_CR44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1126\/scitranslmed.3002648","volume":"3","author":"JT Dudley","year":"2011","unstructured":"Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011;3:96\u2013176.","journal-title":"Sci Transl Med"},{"key":"522_CR45","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/ecco-jcc\/jjz050","volume":"13","author":"N Vande Casteele","year":"2019","unstructured":"Vande Casteele N, Baert F, Bian S, et al. Subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in Crohn\u2019s disease: a prospective multicentre study. J Crohns Colitis. 2019;13:1248\u201356.","journal-title":"J Crohns Colitis"},{"key":"522_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.clinthera.2019.11.010","volume":"42","author":"OJ Adedokun","year":"2020","unstructured":"Adedokun OJ, Xu Z, Liao S, et al. Population pharmacokinetics and exposure-response modeling of golimumab in adults with moderately to severely active ulcerative colitis. Clin Ther. 2020;42:157\u201374.","journal-title":"Clin Ther"},{"key":"522_CR47","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/apt.13243","volume":"42","author":"M Rosario","year":"2015","unstructured":"Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn\u2019s disease. Aliment Pharmacol Ther. 2015;42:188\u2013202.","journal-title":"Aliment Pharmacol Ther"},{"key":"522_CR48","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/jcph.1582","volume":"60","author":"Y Xu","year":"2020","unstructured":"Xu Y, Hu C, Chen Y, et al. Population pharmacokinetics and exposure-response modeling analyses of ustekinumab in adults with moderately to severely active ulcerative colitis. J Clin Pharmacol. 2020;60:889\u2013902.","journal-title":"J Clin Pharmacol"},{"key":"522_CR49","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40262-018-0704-z","volume":"58","author":"AA Suleiman","year":"2019","unstructured":"Suleiman AA, Khatri A, Minocha M, et al. Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn\u2019s disease: analyses of phase I and II trials. Clin Pharmacokinet. 2019;58:375\u201387.","journal-title":"Clin Pharmacokinet"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00522-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00522-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00522-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T17:35:56Z","timestamp":1666632956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00522-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00522-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"21 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was supported through the Litwin IBD Pioneers Program (#623346).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mehak Bassi: None. Siddharth Singh: Research grants from AbbVie, Pfizer, and Janssen; Personal fees from Pfizer (for ad hoc grant review).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This is a review of published literature, without generation of new data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MB and SS were both involved in study concept and design, acquisition of data, analysis and interpretation, drafting and critical revision, and final approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}